Predictive implications of bone turnover markers after palliative treatment with 186Re-HEDP in hormone-refractory prostate cancer patients with painful osseous metastases
- 7 August 2009
- journal article
- clinical trial
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 37 (1) , 103-113
Abstract
To prospectively evaluate the predictive value of various bone formation and resorption markers in patients with bone metastases from prostate cancer after palliative treatment with 186Re-1,1-hydroxyethylidene diphosphonate (186Re-HEDP). Included in the study were 36 men with prostate cancer, suffering from painful osseous metastases and treated with 186Re-HEDP. None had received any treatment that would have interfered with bone metabolism before 186Re-HEDP treatment or throughout the follow-up period. For each patient, pretreatment and posttreatment serum levels of osteocalcin (OC), bone alkaline phosphatase (BALP), aminoterminal (PINP) and carboxyterminal (PICP) propeptides of type I collagen, amino-terminal (NTx) and carboxyterminal (CTx) telopeptides of type I collagen and their combinations were compared with the level and duration of pain response to radionuclide treatment. Pain response was correlated only with pretreatment ΝΤx/PINP, PICP/PINP and NTx/CTx ratios and posttreatment decrease in baseline NTx and PICP values (p=0.0025–0.035). According to multivariate and ROC analyses, the best marker-derived predictors of better and longer duration of response to 186Re-HEDP treatment were a posttreatment decrease in NTx of ≥20% (RR=3.44, p=0.0005) and a pretreatment NTx/PINP ratio of ≥1.2 (RR=3.04, p=0.036) NTx, a potent collagenous marker of bone resorption, along with the novel NTx/PINP ratio provide useful cut-off values for identifying a group of patients suffering from painful osseous metastases from hormone-refractory prostatic carcinoma who do not respond to palliative treatment with 186Re-HEDP. This information could help avoid an inefficient and expensive radionuclide treatment. Also, in the cohort of patients who will eventually undergo such treatment, the medium-term posttreatment changes in NTx offer valuable predictive information regarding long-term palliative response.Keywords
This publication has 44 references indexed in Scilit:
- EANM procedure guideline for treatment of refractory metastatic bone painEuropean Journal of Nuclear Medicine and Molecular Imaging, 2008
- Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acidCancer, 2008
- Cancer Statistics, 2008CA: A Cancer Journal for Clinicians, 2008
- Combined use of zoledronic acid and 153Sm-EDTMP in hormone-refractory prostate cancer patients with bone metastasesEuropean Journal of Nuclear Medicine and Molecular Imaging, 2007
- Suppression of bone density loss and bone turnover in patients with hormone‐sensitive prostate cancer and receiving zoledronic acidBJU International, 2007
- Markers of Bone Metabolism and Survival in Men with Hormone-Refractory Metastatic Prostate CancerClinical Cancer Research, 2006
- Bone Turnover Markers as Predictors of Skeletal Complications in Prostate Cancer, Lung Cancer, and Other Solid TumorsJNCI: Journal of the National Cancer Institute, 2005
- Biochemical Markers and Skeletal MetastasesClinical Orthopaedics and Related Research, 2003
- Osteocalcin: Is it a useful marker of bone metastasis and response to treatment in advanced prostate cancer?The Prostate, 1992
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958